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Reproducible and highly sensitive detection of the broad spectrum epithelial marker keratin 19 
in routine cancer diagnosis
Aims: In this study the recently developed keratin 19 
antibody RCK108 is biochemically and immunohisto- 
chemically characterized. Its applicability as a keratin 
marker in routinely processed histological tissue speci­
mens is assessed.
Methods and results: The keratin 19 antibody RCK108 
antibody was tested on normal and malignant routinely 
formalin-fixed, paraffin-embedded tissue specimens. It 
stains most, although not all, glandular epithelia and 
showed (focal) reactivity in the basal cell compartment of 
stratified epithelia. It was found to react with most 
epithelial tumours, including adenocarcinomas, squamous 
cell carcinomas and endocrine tumours of various origins,
Conclusions: Its reproducible and highly sensitive stain­
ing characteristics make RCK108 a useful antibody to
Keywords: antigen retrieval, carcinoma diagnosis, immunohistochemistry, keratin 19, RCK108
Introduction
Human keratins comprise a family of «  30 different
members, found almost exclusively in epithelial tissues.
Of these, 20 have been found in the ‘soft’ epithelia, while
others belong to the ‘hard' keratins of nail and hair.
Depending on molecular weight and isoelectric pH, the
former keratin subtypes have been classified from 1 to
1 1
20 according to the Moll catalogue ' . Keratins have
Address for correspondence: Dr EH.L.Kwaspen, DCS Innovative 
Diagnostik Systeme, Duvenstedter Damm 52a, D-22397 Hamburg, 
Germany.
been divided into two categories, i.e. the type I keratins 
(neutral or basic; comprising keratins 9 through 20) 
and the type II keratins (acidic; comprising keratins 1 
through 8 ), which form heteropolymers. Based on gel 
electrophoresis and immunohistochemical tissue dis­
tribution studies, the keratin content in both normal 
and neoplastic tissues has been determined to a large 
extent1-4. These studies demonstrate that the distribu­
tion of individual keratins in epithelial tissues is not
j
random, but complies to certain rules . The keratin 
content of glandular epithelia, for example, comprises 
combinations of keratins 7, 8 , 18, 19, or 20, depending
be applied as a broad epithelial marker for carcinoma 
detection in routinely processed paraffin sections. As 
such, RCK108 is a specific reagent for practically all 
epithelial tumours. A few types of epithelial malignan­
cies, known not to contain keratin 19, were negative for 
RCK108. Therefore the antibody is also useful in some 
narrow differential diagnostic considerations such as 
cholangiocellular carcinoma (RCK108 positive) vs. 
hepatocellular carcinoma (RCK108 negative). Another 
important feature of this antibody is that it shows very 
little reactivity in mesenchymal tissues, or mesenchy- 
mally derived tumours, as is frequently described for 
other keratin antibodies. A few leiomyosarcomas 
showed sporadic reactivity.
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on the tissue type in which they occur. More complex 
epithelia, such as stratified epithelia or combined 
epithelia, have a more complex keratin composition. 
In general, such stratifying tissues do not contain the 
glandular type keratins, but express, amongst others, 
keratins 1, 4, 10, 13 or 16, depending on their level of 
differentiation. In this respect, keratin 19 has an 
intermediate position, being observed in both glandular 
and stratified epithelia, albeit in the basal cell compart­
ment of the latter. The presence of keratin 19 in normal 
cells has been related to functional growth, keeping 
post-stem cells in a flexible state of differentiation5“7. As 
cells differentiate, the appropriate epithelium-specific 
type I keratin can be exchanged with keratin 197. This 
hypothesis may explain the ubiquitous presence of 
keratin 19 in proliferative compartments of epithelia. 
This may also explain the widespread expression of 
keratin 19 in premalignant and malignant cells .
A diagnostic ally important aspect of keratins is that 
their tissue-specific expression pattern is retained 
during epithelial malignant transformation. Also, the 
keratin phenotype of a metastatic carcinoma may be. 
indicative of the primary location of the carcinoma1-4. 
One of the major drawbacks in the applicability of 
monoclonal keratin antibodies is that they often lack 
reactivity in formalin-fixed, paraffin-embedded tissue4,8, 
Even after considerable modifications8 to staining 
protocols, many keratin antibodies remain unreactive. 
However, enhancement procedures based on proteolytic 
pre-treatment8 or microwave-based antigen retrieval 
techniques9 have been shown to result in a remarkable 
increase in immunoreactivity. We describe the develop­
ment and characterization of a new monoclonal anti­
body to keratin 19 that displays a sensitive and specific 
reaction in the detection of carcinomas in formalin- 
fixed, paraffin-embedded tissues after microwave oven 
pre-treatment.
Materials and methods
PREPARATION  OF A N T IB O D Y  R C K 1 0 8
The mouse monoclonal antibody producing clone 
RCK108 was obtained after fusion of SP2/0-Agl4 
myeloma cells with splenic lymphocytes from a BALB/c 
mouse, immunized intraperitoneally with a cytoskeletal 
preparation of T24 cells. Fusion was carried out in 
polyethylene glycol-4000 and hybrids were grown in 24- 
well clusters in Roswell Park Memorial Institute medium 
1640 (Dutch modification) containing 15% fetal calf 
serum, The cells were incubated a few hours before 
adding hypoxanthine, aminopterin and thymidine to the 
medium. Hybridoma cultures were tested for antibody
production 2 weeks later (see Results section). Antibody 
RCK 108 is of the IgGl subtype and is available from 
BioGenex (San Ramon, USA), DAKO A/S (Glostrup, 
Denmark) and Euro-Diagnostica BV (Arnhem, The 
Netherlands).
GEL ELECTROPHORESIS AND IMMUNOBLOTTING
One- and two-dimensional polyacrylamide gel electro­
phoresis and immunoblotting assays of cy to skeletons, 
prepared from several cell lines by extraction with 1% 
Triton X-100 in phosphate-buffered saline (PBS), pH
7.4, containing 0.4 him phenylmethyl sulphonyl fluor­
ide, 1 him EGTA and 1 mM EDTA, were performed 
essentially as described before10. The cell lines used for 
these studies were chosen on the basis of their known 
keratin expression patterns and included MCF-7, T24, 
RT4, HeLa, MR65, as well as the human squamous cell 
carcinoma cell line HaCaT. The immunoglobulin sub- 
type of RCK108(IgG, kappa) was determined by the 
mouse monoclonal antibody isotyping kit from IIBT 
(purchased from Gibco BRL, Gathersburg, MD, USA). 
Other antibodies used in this study were LP2K (keratin 
19), CK18-2 (keratin 18), M20 (keratin 8 ), and 
RCK105 (keratin 7). Antibodies M2 0 , RCK105 and 
CK18-2 are available from Eurodiagnostica BV, 
Arnhem, The Netherlands.
TISSUES
Formalin-fixed, paraffin-embedded tissue blocks were 
taken from the files of the Department of Pathology of 
the Canisius Wilhelmina Hospital, Nijmegen, The 
Netherlands. They represented both benign and 
malignant tumours as well as normal epithelial tissues 
(see Table 1 and Table 2). All tissue fragments had 
been fixed in 4% buffered (PBS, pH 7.4) formalin for at 
least 24 h before processing through paraffin for 
routine diagnosis.
IM M U N O H IS  TO CHEMISTRY
Four-micrometre thick sections were cut, mounted on 
poly-L-lysine coated slides, and deparafiinized in xylene 
followed by an ethanol series. After antigen retrieval 
using the microwave procedure with distilled water (see 
below), the sections were incubated for 30m in at room 
temperature, with the RCK108 antibody in a dilution of 
1:10-1:50. After three subsequent washing steps in 
PBS, the SuperSensitive StreptAvidin detection kit 
(BioGenex Laboratories, San Ramon, USA) was applied 
to the sections, according to the manufacturer’s 
instructions. The enzyme label used in most cases,
© 1997 Blackwell Science Ltd, Histopathology, 31, 503-516.
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was horseradish peroxidase in combination with 0.03% 
H?0 -> as substrate and 3,3/-diaminobenzidine-FICl
(DAB) as chromogen. In these cases the endogenous 
peroxidase activity was blocked by quenching for 
15 m in in 3% B.202 in distilled water. In those cases 
where a nonspecific DAB reaction was to be expected 
(e.g. liver), or where a differentiation between the DAB 
reaction product and pigment (e.g. skin) might lead to 
interpretation difficulties, the alkaline phosphatase 
enzyme label was used in combination with 1% 
naphthol AS-MX as substrate and Fast Red in 0,1m  
Tris-HCl pH 8.2 as chromogen. The sections were 
counterstained with haematoxylin and mounted in the 
appropriate mounting medium.
Results
IDENTIF ICATION OF THE R C K 108  ANTIGEN
Antibody RCK108 was initially selected on the basis of 
its reactivity with filamentous structures in cultured 
epithelial cells. The immunofluorescence staining pat­
tern in T24 cells suggested reactivity with one of the 
intermediate filament protein (IFP) types in these cells, 
i.e. keratin or vimentin. Testing of vimentin negative 
cells (MCF-7 and HaCaT) excluded this type of IFP as 
antigen. Immunohistochemical testing of a restricted 
set of human tissues showed that RCK108 was 
exclusively staining epithelia, providing further support 
for the assumption that the reagent recognizes leer a- 
tin(s). When hepatocytes and human skin, tissues 
known not to contain keratin 19, were tested, 
RCK108 staining was negative. Tissues known to 
contain keratin 19 (in addition to other keratins) were 
all positive for RCK108. To further test the assumption 
that RCIC108 recognizes keratin 19, cytoskeleton 
preparations from T24, RT4, and HaCaT cells were 
separated by one- and two- dimensional gel electro­
phoresis and immunoblotted. In all three cell lines, 
RCK108 recognized a single protein band of 40kDa, 
comigrating with a band that was recognized by 
antibody LP2K, known to detect keratin 19 specifically 
(Figure la-g). Two-dimensional immunoblotting 
studies finally confirmed that RCK108 reacts exclusively 
with keratin 19. Figure 2 shows the immunoblots of 
both HaCaT cells (Figure 2a-d) and RT4 (Figure 2e-h), 
subsequently incubated with RCK108, keratin 18 
antibody CK18--2, keratin 8 antibody M20 and the 
keratin 7 antibody RCK105. RCK108 recognized a 
single spot in the two-dimensional immunoblot, migrat­
ing at the correct keratin 19 position as compared to the 
other keratins.
REACTIVITY OF THE KERATIN 19 ANTIBODY RCK108  IN 
TISSUE SPECIMENS
In a pilot study, we tested the reactivity of the RCK108 
antibody on paraffin sections with and without 
pretreatment of slides with a 0.1% pronase (Sigma, 
Deisenhofen, Germany, Pronase XIV) solution in PBS, 
incubated for lOm in at 37°C prior to the primary 
antibody incubation. Also, microwave oven based 
antigen retrieval procedures9 were tested, incubating 
the slides in 0.01 m  citrate buffer pH 6.0, 1% periodic 
acid in distilled water, or distilled water. The sections 
were placed in the test solution and microwaved for two 
cycles of 5 min each at 750 W, after which they were left 
in this solution for 20 min, subsequently rinsed in 
distilled water and PBS, and then used for immunos- 
taining as described above. The tissues used in this pilot 
study comprised nine adenocarcinomas of the mam­
mary gland, 10 carcinomas of the thyroid gland 
(papillary, follicular and medullary), six transitional 
cell carcinomas of the urinary bladder (grade II and III) 
and six adenocarcinomas of the stomach. Optimal and 
reproducible results were obtained after the microwave 
oven based antigen retrieval procedure with distilled 
water. This method was used for all further immunos- 
taining assays.
The reactivity patterns of RCK108 in paraffin- 
embedded normal and malignant tissues are listed in
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Figure 1. One-dimensional immunoblotting of a cytoskeletal pre­
paration of HaCaT cells. Lane a: molecular weight marker proteins: 
lane b: total protein pattern of HaCaT cytoskeleton preparation; lane 
c: immunoblotting with RCK108; lane d: as lane c, but re-incubated 
with keratin 18 antibody CK18-2; lane e: as lane d, but re-incu­
bated with keratin 7 antibody RCIC105; lane f: immunoblotting with 
keratin 19 antibody LP2K; lane g: as lane f, but re-incubated with 
keratin 8 antibody M20. Keratins are indicated by their respective 
numbers.
© 1997 Blackwell Science Ltd, Histoputhology, 31, 503-516.
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Tissue Reactivity patterns
Skin
Epidermis 
Basal layer 
Superficial layers 
Merkel cells 
Sebaceous gland 
Hair follicle 
Hair bulb
External root sheath 
Internal root sheath 
Eccrine sweat gland
Secretory coil — clear cells
—-dark cells 
— myoepithelial cells 
Secretory duct— luminal cells
— peripheral cells 
Lip, non-keratinizing squamous epithelium 
Tongue, non-keratinizing squamous epithelium 
Larynx, non-keratinizing squamous epithelium 
Mesothelium 
Respiratory tract 
Lung
Bronchi
Columnar ciliated epithelial cells 
Basal cells 
Alveoli
Alveolar lining ceils 
Gastrointestinal tract 
Salivary glands 
Parotid gland
Secretory cells — cuboidal cells
—basal cells 
Intercalated ducts —cuboidal cells
—basal cells 
Striated ducts — cuboidal cells
—basal cells 
Intralobular ducts — cuboidal cells
—basal cells
Minor salivary gland 
Ductal epithelium 
Acinar epithelium 
Basal cells
Oesophagus, non-keratinizing squamous epithelium—basal cells
suprabasal cells
Stomach
Antrum—mucous secreting cells
— gastric glands 
Corpus —mucous secreting cells
gastric glands 
neuroendocrine cells
S/+
+
H—h
F/
+ + - f
++
H—I—b
_]_j_
+
f - f
+++ 
H—I—h 
+■
+■
+•
F/+++
F/+
F / H—h 
_ l — [ _
++
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Table 1 /continued....
Tissue Reactivity patterns
Small intestine
Villus epithelium 
Crypt epithelium 
Brunner gland epithelium 
Colon
Epithelium
Pancreas
Ductal epithelium 
Acinar epithelium 
Islets of Langerhans 
Liver
Hepatocytes 
Bile duct epithelium 
Gallbladder 
Epithelium 
Female genital tract 
Mammary gland 
lobules
Ducts
columnar cells 
myoepithelium 
columnar cells 
myoepithelium
Cervix
Endocervix
Ectocervix
columnar cells 
reserve cells 
basal cells 
suprabasal cells 
glandular epitheliumEndometrium - 
Ovary
Surface epithelium 
Placenta
Cytotrophoblast 
Male genital tract 
Prostate
Ductal epithelium 
Basal cells 
Seminal vesicle 
Testis
Sertoli cells/germ cells 
Leydig cells 
Rete testis 
Urinary tract 
Kidney
Epithelium of Bowman’s capsule 
Proximal tubular epithelium 
Distal tubular epithelium 
Collecting duct epithelium 
Henle’s loop epithelium 
Urinary bladder
Transitional epithelium
H—I—h 
++
_{—I—1_
F /+ +
-H—h
f++
+H—h
H —h
4»|iv« I | II
+++
4-+
F/+ 
_(—|—1_
++
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Table 1 /continued....
Tissue Reactivity patterns
Endocrine tissue 
Thyroid gland
Follicle epithelium F/+
Parathyroid gland
Epithelium —
Adrenal gland
Cortex —
Miscellaneous 
Muscle tissue
Skeletal muscle —
Cardiac muscle —
Smooth muscle —
Vascular endothelium —
Blood cells
Erythrocytes —
Lymphocytes —
Peripheral nerve tissue —
Fibroblasts —
Bone tissue
Osteocytes —
Osteoblasts —
Chondrocytes
Unless otherwise indicated, positive cases showed a reaction in 50% to 100% of the cells,
S, scattered cells are stained (less than 5%); F, focal staining pattern (5% to 50% of cells are stained); +, weak staining reaction; 
+-h moderate staining reaction; ++-K strong staining reaction; negative,
Tables 1 & 2. As the tables give detailed information, we RCK 108. The basal cell compartments of non­
describe only the most salient features of the keratin 19 keratinizing squamous epithelia were usually positive
distribution patterns. for keratin 19. In the oral cavity focal staining, limited
In normal epithelia, all columnar cells showed to the basal cell compartment, was observed, Epithelia
reactivity with RCK108 to a variable extent, with the lining tongue and lip were negative. In some cases the
exception of secretory cells of the parotid gland and keratinizing squamous epithelium of the skin showed a
Brunners’ glands in the duodenum. Thyroid epithelium weak and scattered expression of RCK108 in the basal
was focally and weakly positive for RCK 108. In liver, 
bile duct epithelium was strongly positive while 
hepatocytes were negative. Complex columnar epithe­
lia, such as breast and eccrine sweat glands, showed 
intense staining of columnar cells lining the ducts, but
cell layer, which may represent staining in Merkel cells.
When tested in epithelial malignancies, RCK 108 
reactivity was detectable in all adenocarcinomas 
examined (Figure 3a,b). The antibody allowed a clear 
identification of adenocarcinoma cells dispersed
the myoepithelium was negative for RCK 108. The throughout epithelium of Paget's disease (Figure 3c). 
myoepithelial cells adjacent to the secretory cells of the Also the three main types of thyroid gland tumours
(Figure 3d,e,f) were positive. As opposed to cholangio- 
cellular carcinomas, which were all RCK 108 
positive (Figure 3g), hepatocellular carcinomas 
were negative (Figure 3h). Neuroendocrine carcinomas
parotid gland were also negative. Prostatic basal cells 
however, were positive for keratin 19; basal cells of the 
minor salivary glands and basal cells lining intercalated, 
striated and interlobular ducts of the parotid were also
positive for RCK 108. Reserve cells in the endocervix of the pituitary gland (Figure 3i) and lung (Figure 3j)
were all positive for RCK 108. Transitional epithelia 
lining the urinary tract showed intense staining 
through their full thickness. Muscle tissues, endothelial 
cells, bone marrow and fibroblasts were negative for
were positive, irrespective of their classification. Tran­
sitional cell carcinomas (Figure 3k) showed a strong 
reaction with the RCIC108 antibody. Non-keratinizing 
squamous cell carcinomas of the lung, cervix
© 1997 Bliickwell Science Ltd, Histopathology, 31, 503-516.
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Table 2. RCK108 staining reaction patterns in formalin-fixed malignant human tissues
Tissue Proportion of positive cases Reactivity patterns
Skin
Intradermal naevus 
Compound naevus 
Actinic keratosis 
Bowen’s disease 
Basal cell carcinoma 
Keratoacanthoma
Well-differentiated keratinizing squamous cell carcinoma 
Poorly differentiated keratinizing squamous cell carcinoma 
Melanoma
Lip
Basal cell carcinoma
Well-differentiated non-keratinizing squamous cell carcinoma 
Moderately differentiated squamous cell carcinoma 
Tongue
Well-differentiated squamous cell carcinoma 
Moderately differentiated squamous cell carcinoma 
Poorly differentiated squamous cell carcinoma 
Nasopharynx
Papilloma; transitional epithelium 
Inverted papilloma; transitional epithelium 
Larynx
Well-differentiated squamous cell carcinoma 
Moderately differentiated squamous cell carcinoma 
Poorly differentiated squamous cell carcinoma 
Mesothelioma 
Respiratory tract
Squamous cell carcinoma
Moderately differentiated squamous cell carcinoma 
Poorly differentiated squamous cell carcinoma 
Adenocarcinoma
Well-differentiated adenocarcinoma 
Moderately differentiated adenocarcinoma 
Poorly differentiated adenocarcinoma 
Adenosquamous carcinoma 
Small cell lung carcinoma 
Gastrointestinal tract 
Parotid gland
Pleomorphic adenoma 
Mucoepidermoid carcinoma 
Epidermoid component 
Mucinous component 
Acinic cell carcinoma 
Oesophagus
Well differentiated squamous cell carcinoma 
Moderately differentiated squamous cell carcinoma 
Stomach
Adenocarcinoma
Carcinoid
Lymph node metastasis of gastric adenocarcinoma 
Small intestine 
Adenocarcinoma
0/1
0/1
0/1
0/2
4/4
1/1
3/3
0/1
0/3
0/1
1/3
0/5
1/2
1/5
1/1
1/1
3/3
1/3
3/4
1/1
2/2
6/6
1/1
1/1
2/2
1/1
1/1
5/5
5/5
1/1
2/2
1/1
3/3
3/3
4/4
2/2
1/1
F/+
F/+
F/+
F/+
+
F/+
_|—I—|_
F/~}~
F/+
F/+
■+ 
+++
_ j — j— f _  
_ l — 1_ _ | _  
+ + +  
H—I—h
H—h
+++
H—I—b 
H—I—b
+++ 
■+
f + +
1/1 ++
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Tabìe 2 /continued....
Tissue Proportion of positive cases Reactivity patterns
Appendix
Carcinoid
Colon
Well-differentiated adenocarcinoma 
Moderately differentiated adenocarcinoma 
Lymph node metastasis of colon adenocarcinoma 
Carcinoid (goblet cell type)
Pancreas
Well differentiated adenocarcinoma 
Liver
Hepatocellular carcinoma 
Cholangiolocellular carcinoma 
Mammary gland 
Ductal carcinoma 
Lobular carcinoma 
Combined ductal/lobular carcinoma 
Lymph node metastasis of ductal carcinoma 
Paget’s disease 
Female genital tract 
Ovary
Cystadenocarcinoma 
Serous type 
Mucinous type 
Endometroidcarcinoma 
Malignant Brenner tumour 
Clear cell carcinoma 
Cervix
Squamous cell carcinoma 
Large cell non-keratinizing 
Small cell non-keratinizing 
Adenocarcinoma 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Adenosquamous carcinoma 
Clear cell carcinoma 
Endometrium
Well-differentiated endometrioid carcinoma 
Poorly differentiated endometrioid carcinoma 
Adenosquamous carcinoma 
Vulva
Well-differentiated squamous cell carcinoma 
Moderately differentiated squamous cell carcinoma 
Male genital tract 
Prostate
Well differentiated adenocarcinoma 
Moderately differentiated adenocarcinoma 
Poorly differentiated adenocarcinoma 
Testis
Seminoma
Malignant teratoma, intermediate type 
Choriocarcinoma
1/1
2/2
9/9
2/2
1/1
7/7
0/9
6/6
12/12
4/4
4/4
2/2
2/2
5/5
6/6
7/7
1/1
2/2
2/2
2/2
7/7
1/1
4/4
8/8
2/2
9/9
4/4
3/3
5/5
1/4
F/+
H—I—h
w|<««
_ j — 1_
I
++4
H—I—h 
4-4-4- 
H—I—h 
++ 
4-4-
f - f
f-f
H—I—h 
4-4-4- 
4-4-4-
4-4-
4-4- 
H—I—h
4~h
F/+
F / -|—|—j-
4/4 WVWW
3/3 4 - 4 -
1/1 F/+
Oil
3/3 -j— 1_
2/2 + + +
© 1997 Blackwell Science Ltd. tiistopathology, 31, 503-516.
Cytokeratin 19 in cancer diagnosis 511
Table 2 /continued....
Tissue Proportion of positive cases Reactivity patterns
Embryonal cell carcinoma 0/1 —
Sertoli cell tumour 0/1 —
Urinary tract
Kidney: renal cell carcinoma 6/6
Urinary bladder; transitional cell carcinoma (grades 2 & 3) 9/9 +++
Endocrine tissues
Thyroid gland
Papillary carcinoma 212 >i | •
Follicular carcinoma 4/4 ++
Medullary carcinoma 2/2 _j |_
Adrenal gland
Phaeochromocytoma 0/2 —
Pituitary gland
Chromophobic adenoma 1/1 ++
Acidophil adenoma 1/1 _j—1_
Neuronal epithelial tissues
Astrocytoma (grades 2-4) 4/4 H—h
Neurofibroma 0/2 —
Meningioma 4/4 _j—j_
Miscellaneous
Lymphoma
Non-Hodgkin
Centrocytic 0/2 —
Centroblastic 0/2 —
Hodgkin’s disease 0/2 —
Nodular sclerosing 0/1 —
Chondrosarcoma 0/1 —
Osteosarcoma 0/1 —
Malignant fibrous histiocytoma 0/2 —
Synovial sarcoma 0/1 —
Lipoma 0/2 —
Fibroma 0/2 —
Leiomyosarcoma 5/13 S/++
Unless otherwise indicated, positive cases showed a reaction in 50% to 100% of the cells.
S, scattered cells are stained (less than 5%); F, focal staining pattern (5% to 50% of cells are stained); +f weak staining reaction; 
■+, moderate staining reaction; 4*++. strong staining reaction; —, negative.
(Figure 31), vulva, oral cavity and oesophagus cell carcinomas were negative. Furthermore, phaeo- 
(Figure 3m) were positive with some variation in chromocytomas, lymphomas, chondrosarcomas and 
immunostaining intensity between the cases. Focal 
positivity was observed in three out of four keratin­
izing squamous cell carcinomas and in all basal cell
osteosarcomas were negative.
Of the non-epithelial malignancies, all gliomas 
showed strong focal positivity in tumour cells 
carcinomas (Figure 3n). Benign lesions of the skin (Figure 3o). Some leiomyosarcomas showed immuno- 
were negative. Pleomorphic adenomas of the salivary reactivity with the RCK108 antibody, the number 
gland were strongly positive, with a negative basal of positive cells ranging from 1% to 1 0% staining 
cell component. In some testicular teratomas we with various staining intensities and one epithelioid
noted reactivity in the epithelial component, while 
Sertoli cell tumours, seminomas and embryonal
leiomyosarcoma showing weak reactivity in virtually 
all tumour cells.
© 1997 Blackwell Science Ltd, Histopathobgy, 31, 503-516.
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Figure 2. Two-dimensional blots 
of cytoskeletal preparations of 
RT4 cells (a-d) and HaCaT cells 
(e-f), subsequently (re)incubated 
with RCIC108 (a, e), keratin 18 
antibody CK18-2(b, I), 
keratin 8 antibody M20 (c, g) and 
keratin 7 antibody RCIC105(d, h).
Keratins are indicated by their 
respective numbers.
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Discussion
When immunohistochemical tests are applied in 
tumour diagnosis, antibody panels invariably contain 
at least one keratin antibody, usually detecting a broad 
spectrum of keratins, such as Lu5 or a mix of AE1 and 
AE3, often combined with CAM5.211. Since the 
detectability of keratins in routinely processed tissue 
samples varies, there is a continuous search for keratin 
antibodies that reproducibly recognize their epitope in
formalin-fixed, paraffin-embedded tissue with a high 
epitope affinity. Furthermore, much effort has been 
directed toward enhancing accessability of antigens in 
such specimens9. The keratin antibody RCK108 is 
particulary promising, not only because of the wide 
tissue distribution of its keratin 19 antigen^ but also 
because of its unusually intense and specific immunor- 
eactivity in paraffin sections, which is limited to the 
epithelial cells and not seen in the surrounding 
mesenchymal tissues or mesenchymally derived
Figure 3, Staining reactions with the keratin 19 antibody RCK108 in epithelial malignancies, a, Adenocarcinoma of the stomach; 
b, adenocarcinoma of the prostate; c, Paget’s disease; d, follicular carcinoma of the thyroid; e, medullary carcinoma of the thyroid; f, papillary 
carcinoma of the thyroid; g, cholangiolocellular carcinoma; h, hepatocellular carcinoma; i, small cell lung carcinoma; ], pituitary adenoma; 
k, transitional cell carcinoma of the urinary bladder; 1, squamous cell carcinoma of the cervix; m, squamous cell carcinoma of the 
oesophagus; n, basal cell carcinoma of the skin; and o, astrocytoma,
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tumours (for discussion of the few exceptions, see 
below). The protocol to be applied for optimal immu- 
nostaining comprises a simple microwave pre-treatment 
step.
COMPAR ISON  OF RCK108  REACTIV ITY  TO OTHER 
KERATIN  19 ANTIBODIES
A number of keratin 19 antibodies have been developed 
and applied in diagnostic pathology. Of these Ks 19-2 
and RCIC108 stain formalin-fixed, paraffin-embedded 
tissues12“ 14 after protease or microwave pretreatment, 
respectively. Other studies investigating keratin 19 
distribution3' 7,15-24 used fresh frozen tissue or metha- 
cam-fixed tissues.
The reactivity patterns of RCK108 in paraffin-
embedded normal tissues are largely comparable to
the patterns observed in frozen tissue specimens tested
with the other keratin 19 antibodies. However, some
interesting discrepancies were noted. Born et cd.20 and
Burns et al.21, for example, noted keratin 19 staining in
the myoepithelial cells of the secretory part of the“1
parotid gland, although Burns et air indicated that it 
was difficult to discern these cells from overlying 
columnar cells. We could not detect keratin 19 in the 
myoepithelial cells of the parotid, mammary gland, 
salivary gland and sweat glands, which is in accord with 
the literature1,22. Basal cells of the salivary gland ducts 
and prostate, as well as the endocervical reserve cells 
showed keratin 19 expression. This may imply that 
bona fide myoepithelial cells can be distinguished from 
potentially proliferative basal cells on the basis of 
keratin 19 expression. Moreover, Bartek et al.16,23, 
Taylor et a l and Dalai et al~ ’ noted heterogeneity in 
keratin 19 staining of luminal epithelial cells of the 
mammary gland, with absence of keratin 19 in some 
cells of small ducts and terminal ductal lobular units. In 
the underlying study, RCK108 stained all luminal cells 
in the mammary gland. This discrepancy may be 
ascribed to differences in the epitopes recognized by 
the various antibodies used16,23,25'26, as well as 
technical aspects.
In tumours, RCK108 displayed strong reactivity in all 
types of epithelial malignancies, with the exception of 
hepatocellular carcinoma. When compared to the 
literature, again some discrepancies are worth noting. 
Schelfhout et a l24 showed keratin 19 to differentiate 
between follicular (focal keratin 19 reaction) and 
papillary (strong keratin 19 reaction) thyroid carcin­
oma. In our study, both follicular and papillary thyroid 
carcinoma, and also medullary thyroid carcinoma, 
displayed strong immunoreactivity with the RCK108 
antibody. Apparently, the high affinity of RCK108
© 1997 Blackwell Science Ltd, Uistopatholocjy, 31, 503-516.
detects low(er) concentrations of keratin 19, resulting 
in similar results for both types of thyroid carcinomas.
PRACT ICAL  APPL ICATIONS
Because of its broad reactivity in normal epithelia and 
their malignant counterparts the RCK108 antibody is 
an important keratin immunoreagent to be incorpo­
rated in a basic panel of immunoreagents used for 
carcinoma diagnosis. In case of a positive reaction in a 
poorly differentiated tumour the likelihood of a carcin­
oma is high. In RCK108 negative cases the diagnosis of 
a nonepithelial malignancy should be seriously enter­
tained. A few exceptions, in which this keratin subtype 
is often not detectable, include keratinizing squamous 
cell carcinoma and hepatocellular carcinoma. In 
differential diagnosis, the absence of keratin 19 in 
these cases opens some interesting practical applica­
tions. We found that RCK108 may distinguish between 
hepatocellular carcinoma (keratin 19 negative) and 
cholangiocellular carcinoma (keratin 19 positive), and 
thus be useful within this narrow differential diagnostic 
consideration. However, it has to be kept in mind that 
poorly differentiated hepatocellular carcinomas may 
show a positive reaction with RCK108. Van Eyken et 
a l27,2H reported a positive keratin 19 reaction in some 
poorly differentiated hepatocellular carcinomas, in 
pseudoacinar parts of hepatocellular tumours and in 
hepatoblastoma. These findings are in accord with the 
fact that hepatocytes can transform towards a bile duct 
epithelium phenotype12,27,28. The hepatocellular carci­
nomas in our study were all negative for RCK108, but 
no poorly differentiated hepatocellular carcinomas were 
investigated. Another practical application for RCK108 
results from its capacity to highlight the intraepithelial 
malignant adenocarcinoma cells in Paget’s disease.
The immunoreactivity of many keratin immunorea­
gents with non-epithelial (tumour) cells is largely 
attributed to the presence of the embryonal keratin 8 
and 18 subtypes4. This may lead to a diagnostic 
dilemma between poorly differentiated carcinoma and 
sarcoma. Application of RCK108 circumvents this 
problem to a large extent, although leiomyosarcomas 
were found to express keratin 19 in a small fraction of 
the cells, and astrocytomas showed focal cellular 
positivity for keratin 19 in all cells.
CONCLUSIONS
RCK108 antibody recognizes keratin 19 in formalin- 
fixed, paraffin-embedded tissue with high specificity and 
sensitivity. The results are highly comparable with those 
of other keratin 19 antibodies tested on frozen tissue
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sections. Its reactivity in epithelial malignancies makes 
it very useful as a general carcinoma marker. It is of 
value in the narrow differential diagnostic considera­
tions of hepatocellular carcinoma vs. cholangiocellular 
carcinoma and Paget’s disease.
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